Table 6.

Response assessment by TP53 mutation status in patients with MYD88WT

Total (n = 20)TP53WT (n = 16)TP53MUT (n = 4)
Best overall response, n (%) 
CR 1 (5.0) 1 (6.3) 0 (0.0) 
VGPR 3 (15.0) 3 (18.8) 0 (0.0) 
PR 8 (40.0) 6 (37.5) 2 (50.0) 
MR 4 (20.0) 3 (18.8) 1 (25.0) 
SD 3 (15.0) 2 (12.5) 1 (25.0) 
PD 1 (5.0) 1 (6.3) 0 (0.0) 
VGPR or better, n (%) 4 (20.0) 4 (25.0) 0 (0.0) 
Major response, n (%) 12 (60.0) 10 (62.5) 2 (50.0) 
Time to response, median (min, max), mo 
VGPR or CR 9.6 (2.8, 22.1) 9.6 (2.8, 22.1) 
Major response 3.4 (1.8, 44.6) 3.3 (1.8, 44.6) 4.3 (3.0, 5.5) 
Total (n = 20)TP53WT (n = 16)TP53MUT (n = 4)
Best overall response, n (%) 
CR 1 (5.0) 1 (6.3) 0 (0.0) 
VGPR 3 (15.0) 3 (18.8) 0 (0.0) 
PR 8 (40.0) 6 (37.5) 2 (50.0) 
MR 4 (20.0) 3 (18.8) 1 (25.0) 
SD 3 (15.0) 2 (12.5) 1 (25.0) 
PD 1 (5.0) 1 (6.3) 0 (0.0) 
VGPR or better, n (%) 4 (20.0) 4 (25.0) 0 (0.0) 
Major response, n (%) 12 (60.0) 10 (62.5) 2 (50.0) 
Time to response, median (min, max), mo 
VGPR or CR 9.6 (2.8, 22.1) 9.6 (2.8, 22.1) 
Major response 3.4 (1.8, 44.6) 3.3 (1.8, 44.6) 4.3 (3.0, 5.5) 

Among 20 patients with MYD88WT, 4 patients with TP53MUT had a lower major response rate (50%), and none achieved VGPR or CR, compared with TP53WT patients.

max, maximum; min, minimum; MR, minor response; PD, progressive disease, SD, stable disease.

Close Modal

or Create an Account

Close Modal
Close Modal